Skip to main content
Fig. 1 | Alzheimer's Research & Therapy

Fig. 1

From: Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer’s disease (BLAZE)

Fig. 1

Study disposition. One patient randomized to placebo received one dose of crenezumab treatment and was therefore included in the crenezumab arm of the safety population. IV intravenous, PET positron emission tomography, q2w every 2 weeks, q4w every 4 weeks, SC subcutaneous

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193